Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleed...
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Business Wire
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared to placebo, both in combination with antiplatelet therapyThese results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke, or the severity of the strokeThere was no increase in ISTH major bleeding, and the bleeding risk was similar to placebo for minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage, and fatal bleedingOCEANIC-STROKE enrolled 12,327 patients and is the first successfully completed Phase III trial of a FXIa inhibitor which demonstrated superiority in preventing stroke compared to placebo NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily,
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ CampaignBusiness Wire
- Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in CanadaBusiness Wire
- Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke PreventionBusiness Wire
- Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases [Yahoo! Finance]Yahoo! Finance
- LEGAL NOTICE TO ALL CANADIANS OUTSIDE OF QUÉBEC - NOTICE OF CLASS ACTION CERTIFICATION AND SETTLEMENT APPROVAL HEARING [Yahoo! Finance]Yahoo! Finance